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ABSTRACT  
Introduction: Antiepileptic drug (AED) teratogenicity is suspected to be the main cause of impaired 
development in children of women with epilepsy. However, many factors may confound the reported risks. 
The purpose of this review is to characterize the epilepsy cohort in the Norwegian Mother and Child 
Cohort Study (MoBa) and show how it can be used to detangle various risk factors for adverse outcome in 
children of mothers with epilepsy. 
Methods: MoBa is a large, long-term prospective, family-based cohort study. The database is linked to the 
Medical Birth Registry of Norway. The epilepsy cohort consists of mothers and their children representing 
more than 700 pregnancies. Blood samples were obtained from the mother during pregnancy and from the 
umbilical cord after delivery, and AED concentrations were measured. Validated screening tools deter-
mined the frequency of maternal confounding risk factors and adverse offspring outcomes. Risk estimates 
were reported as adjusted odds ratios with confidence intervals using the remaining MoBa cohort as a 
reference (n=107,597). Outcome in offspring of women with epilepsy without AED treatment in pregnancy 
and of fathers with epilepsy were used to separate the effect of epilepsy from the effect of in utero expo-
sure to AEDs. 
Results: Socioeconomic and psychiatric risk factors for adverse offspring outcomes were more frequent in 
mothers with epilepsy. The frequency of adverse offspring outcome was increased at 6, 18 and 36 months 
for verbal, motor and social development. Children of women with epilepsy without AED treatment and of 
fathers with epilepsy were generally similar to children of women without epilepsy. 
Conclusion: Children of mothers with epilepsy are at risk of adverse outcomes. AED exposure emerges as 
the most important risk factor. 
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Women with epilepsy account for 0.8% of all deliveries 
in Norway, and 0.3-0.5% of newborns have been ex-
posed to antiepileptic drugs (AEDs) in utero (1). Al-
though AED exposure increases the malformation risk 
(2,3), women with epilepsy are usually encouraged to 
continue their medication during pregnancy since 
severe epileptic seizures may cause fetal hypoxia and 
death, and also be harmful to the mother. Reportedly, 
5% of maternal deaths during pregnancy are caused by 
epilepsy (4). 
 Recently, a possible association between fetal AED 
exposure and cognitive deficits and behavioral disor-
ders has emerged (5). In utero AED exposure has been 
linked to lower IQ, delayed motor, verbal and social 
development, and neuropsychiatric disease such as 
autistic disorders and attention deficit hyperactive dis-
order (ADHD) (6-8). However, three major methodo-
logical challenges render the interpretation of these 
findings difficult. First, subjects with epilepsy may dif-
fer from the reference population socioeconomically 
and genetically. Second, the impact of epileptic sei-
zures in pregnancy on the developing child is uncertain 
(9). Third, the relationship between the degree of AED 
exposure and the risk of adverse outcome is not well 
known. In most studies where maternal pre-pregnancy 
AED doses have been included, a dose-effect relation-
ship has been demonstrated (6,10). However, due to 
pharmacokinetic variability, AED blood levels in the 
mother and fetus are not closely correlated to the 
reported dose (11-13). Hence, the degree of fetal AED 
exposure is unpredictable, even when dose information 
is available. 
 The Norwegian Mother and Child Cohort Study 
(MoBa) is well suited to target these three challenges. 
Prospective registration of a multitude of possible risk 
factors for adverse outcomes in the child has been in-
cluded. Through validated screening tools (14-16), the 
woman is evaluated for psychiatric disorders. Hence, it 
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is possible to adjust for and evaluate the effect of 
numerous potential confounding factors. Most impor-
tantly, the population-based family-centered design of 
MoBa enables comparisons with a large, representative 
reference group, as well as with women with epilepsy 
not using AED treatment in pregnancy, and with 
fathers with epilepsy. It is thereby possible to partially 
adjust for the potential genetic and socioeconomic im-
pact of epilepsy, isolating the in utero risk factors, e.g. 
AED exposure. Other large studies of in utero AED 
exposure often determine the effects on the developing 
child by comparing the offspring of women using 
different types of AEDs (3,6,7) or by using children of 
mothers without epilepsy as the only reference (17,18), 
possibly introducing systematic bias. 
 Furthermore, from material stored in the MoBa 
Biobank it is possible to measure AED concentrations 
and other factors possibly involved in AED-induced 
teratogenesis. 
 Investigating the effect of these potential risk factors 
on pregnancy complications and offspring outcomes 
may help to answer why some fetuses are vulnerable to 
unfavorable effects of AED exposure whilst others are 
protected. Studies targeting individual susceptibility 
and teratogenic mechanisms are lacking and highly 
called for (3). Such knowledge will help the clinician 
to identify women with a high risk and guide therapy 
decisions and pre-pregnancy counselling. 
 The purpose of this review is to describe pregnan-
cies in women with epilepsy in the MoBa study and 
summarize findings from research published from this 
cohort so far, as well as to provide an overview of 
ongoing research. We will show how the MoBa study 
can be used to detangle various risk factors for adverse 
outcomes in children born to mothers with epilepsy 
and shed light on groups of mothers at particular risk. 
MATERIAL AND METHODS 
 
Subjects  
The MoBa study is a prospective population-based 
cohort study conducted by the Norwegian Institute of 
Public Health (19). From 1999 to 2008 pregnant wo-
men were invited to participate. There were no exclu-
sion criteria. A detailed study protocol is available at 
www.fhi.no/moba-en. The women consented to parti-
cipation in 40.6% of the pregnancies. Follow-up is still 
ongoing and conducted by extensive questionnaires 
and sampling of biobank material. Information on ma-
ternal epilepsy, other somatic disorders, and medica-
tion reported by doctors and midwives is also available 
through a linkage to the mandatory Medical Birth 
Registry of Norway (MBRN) (20). 
 Our published studies are based on version V-VII of 
the quality-assured data files released for research on 
mothers with epilepsy. Information on the epilepsy 
diagnosis, AEDs and anti-depressive medication was 
obtained from the antenatal MoBa questionnaires Q1 
(gestational weeks 17-19) and Q3 (gestational week 
30) and the MBRN. The epilepsy cohort consisted of 
more than 700 pregnancies. The number of study 
subjects according to data file version and publication 
is given in Table 1. 
 
Validation of the epilepsy cohort and clinical epilepsy 
variables  
A questionnaire was sent to mothers with epilepsy in 
version VII of the data files (n=604) for validation of 
the epilepsy diagnosis and to retrospectively obtain 
supplementary information on pregnancy AED use, 
AED doses, and seizures during pregnancy. To further 
validate the diagnosis and medication use, hospital 
records of the MoBa mothers with epilepsy residing in 
Western Norway were examined (n=40). 
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Outcome variables  
Psychosocial characteristics and psychiatric disease 
We have investigated differences in the occurrence of 
low level of education (12 years or less), low income 
(199,999 NOK or less/yr, equal to 24 000 Euro), un-
employment due to disability, single parenting, depres-
sion and/or anxiety from early pregnancy to 3 years 
after delivery, as well as eating disorders before and 
after pregnancy in in the MoBa cohort (21-23). Curr-
ently, we are investigating the impact of body weight 
increase during pregnancy on pregnancy complications 
in women with epilepsy, including overweight and 
obesity. We are also investigating socioeconomic fac-
tors and psychiatric disease in fathers with epilepsy, as 
well as quality of life parameters and relationship 
satisfaction in women with epilepsy. 
 Validated screening tools to assess psychiatric 
symptoms included short versions of the Hopkins 
Symptom Checklist (SCL-5 and SCL-8) (14,24,25), 
which is designed to detect depression and anxiety in 
population surveys, widely used, and sensitive to psy-
chological distress in epilepsy (26-28). A mean score 
greater than 1.75 was defined as presence of depres-
sion and anxiety as this cut-off has been established 
for the longer version SCL-25 (27). 
 A history of major depression was assessed by the 
Life Time Major Depression Scale (29). Bulimia 
nervosa and binge eating disorder were diagnosed by 
questions based on the Diagnostic and Statistical Ma-
nual of Mental Disorders IV (DSM-IV) (30).  
Child development 
Assessment of child development was based on short 
versions of validated screening tools completed by the 
mothers at child ages 6, 18 and 36 months (31-44). 
The instruments measure whether the child has reached 
critical developmental milestones, or show signs of ab-
normal behavior. To improve the construct validity of 
these scores, we applied cut-off values distant (2 to 3 
standard deviations) from the mean to detect children 
where true impairment was likely. For scales without 
predefined cut-offs, definition of abnormal outcomes 
was based on the 90-95 percentile for the 6-months-old 
children (45) and the 95-98 percentile for 18- and 36-
months-old children (46). Previous MoBa studies 
using the applied screening instruments have shown 
good reliability (32,35,47). At 6 months of age social 
skills, fine and gross motor development and tempe-
rament were evaluated. At 18 and 36 months of age 
social skills, communication skills, gross and fine 
motor development, as well as autistic traits were 
assessed. At 36 months ADHD and aggressive symp-
toms were recorded as well. The screening tools are 
described in detail by Veiby et al. (45,46). The impact 
of breastfeeding on development in children of 
mothers with epilepsy according to AED use was also 
studied (45). 
 
Biobank material  
Blood was drawn from the mother at weeks 17-19 and 
from the umbilical cord immediately after birth. The 
MoBa Biobank extracts plasma and stores the samples 
(48). Analyses of carbamazepine, carbamazepine-
10,11-epoxide, the oxcarbazepine monohydroxyderi-
vative metabolite (MHD), lamotrigine, levetiracetam 
and topiramate were performed in 100 µl plasma with 
liquid chromatography mass spectrometry (LC-MS) 
methods developed at the Department of Clinical 
Pharmacology, St. Olav University Hospital, Trond-
heim, using an Agilent Technologies LC-MSD 1100-
system (Agilent, Palo Alto, California, USA). 
 Carbamazepine, carbamazepine-10,11-epoxide and 
MHD were extracted by a liquid-liquid method and 
separated on a Zobrax SB-C18 (150 x 4.6 mm) column 
(Agilent), using carbamazepine-d10 as internal standard. 
The LC-MS was operated in the positive ionization 
mode, using mass transitions of m/z 237.1>194.1 for 
carbamazepine, 253.1>180.1 for carbamazepine-
10,11-epoxide, 237.1>194.1 for MHD and 247.3 for 
carbamazepine-d10. The limits of quantification were 
2.5 µmol/l for carbamazepine, 0.25 µmol/l for carba-
mazepine-10,11-epoxide and 2.5 µmol/l for MHD, and 
the method was linear at least up to 200, 20 and 200 
µmol/l, respectively, for these analytes. Within-day 
coefficients of variation were better than 3.5% and 
between-day coefficients of variation were better than 
11.7% for the three analytes. 
 Lamotrigine was extracted by a liquid-liquid method 
and separated on a Supelguard Discovery 18 (20 x 4 
mm) column (Supelco/Sigma-Aldrich, St. Louis, 
Missouri, USA), using minoxidil as internal standard. 
The LC-MS was operated in the positive ionization 
mode, using mass transitions of m/z 256.0>211.0 for 
lamotrigine and 210.1>164.1 for minoxidil. The limit 
of quantification was 0.5 µmol/l and the method was 
linear at least up to 100 µmol/l. Within-day coeffici-
ents of variation were better than 0.7% and between-
day coefficients of variation were better than 6.3%. 
 Levetiracetam and topiramate were extracted by a 
liquid-liquid method and separated on a Zobrax Eclipse 
XDB-C8 (150 x 4.6 mm) column (Agilent), using 
levetiracetam-d6 and topiramate-d12 as internal stan-
dards. The LC-MS was operated in the positive ioniza-
tion mode, using mass transitions of m/z 171.1>126.1 
for levetiracetam, 357.2>340.1 for topiramate, 132.0 
for levetiracetam-d6 and 369.2>352.2 for topiramate-
d12. The limits of quantification were 5 µmol/l for 
levetiracetam and 1 µmol/l for topiramate, and the 
method was linear at least up to 500 and 250 µmol/l, 
respectively. Within-day coefficients of variation were 
better than 11.3% and between-day coefficients of 
variation were better than 16.9% for both analytes. 
 Valproate was analysed by a commercial kit using a 
Cobas Integra 400 plus system (Roche Diagnostics, 
Rotkreuz, Switzerland). The limit of quantification 
was 25 µmol/l and the method was linear at least up to 
1000 µmol/l.  
Statistics  
Statistical analyses were performed with SPSS for 
Windows. Categorical characteristics of the epilepsy 
group were compared to the reference group by 
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Pearson’s chi-square test or Fisher’s exact test. 
Continuous variables were compared by independent 
samples t-tests. Dichotomized outcome variables were 
analyzed by logistic regression. Risk estimates were 
presented as crude and adjusted odds ratios (OR) with 
95% confidence intervals (CI) and p-values. The out-
comes were analyzed according to maternal and pa-
ternal epilepsy, with and without prenatal exposure to 
AEDs. To assess potential effects of baseline differen-
ces between the AED exposed and reference groups, 
propensity-score matching was also performed as post 
hoc analyses. Each child in the drug-exposed group 
was matched to a child with very similar propensity 
score, and the risk of adverse outcomes was calculated 
comparing the matched groups. 
 Doses and plasma concentrations were correlated 
with the outcome variables using Spearman’s rank 
correlation test. Two-sided p-values < 0.05 were regar-
ded as statistically significant. 
 
Ethics  
Informed written consent was obtained from all the 
participants. The MoBa study has been approved by 
the Norwegian Data Inspectorate. All sub-studies pre-
sented were approved by The Regional Committee for 
Medical Research Ethics (REK). 
 
 
RESULTS: PUBLISHED DATA AND ONGOING 
RESEARCH 
 
The MoBa epilepsy cohort  
In the validation study, questionnaires retrospectively 
obtaining supplementary data on women with epilepsy 
were completed for 300 pregnancies corresponding to 
306 live born children (50% of the epilepsy cohort). 
According to the questionnaires 98% of the women 
who reported having epilepsy in the original MoBa 
questionnaire confirmed having epilepsy in the retro-
spective survey. The single most frequent self-reported 
type of epilepsy was juvenile myoclonic epilepsy. 
Generalized tonic clonic attacks were reported by 
85%, whereas 52% had experienced absence seizures. 
Seizures during pregnancy and/or birth were reported 
by 17% and 3% respectively. Twenty-one patients 
described generalized tonic clonic (GTC) seizures, 
however only 1 patient had more than 3 such seizures 
in the period. Disease severity was unchanged during 
pregnancy for 86%, whereas 9% claimed that their epi-
lepsy worsened relative to the pre-pregnancy period. 
Self-reported clinical epilepsy characteristics are 
further summarized in Table 2. Characteristics accor-
ding to use of AEDs during pregnancy have also been 
reported (23). 
 In a subcohort of the women, self-reported epilepsy 
in the questionnaires was compared with hospital case 
records. The epilepsy diagnosis was verified for 38 of 
40 mothers. The two patients whose diagnostic confir-
mation could not be obtained were both in the group 
not treated with AEDs. According to the hospital files, 
mothers not treated with AEDs (47.5%) generally had 
inactive epilepsy, as only one of them had experienced 
seizures within 2 years prior to the pregnancy. There 
was 100% agreement between the mothers’ reporting 
of AED use during pregnancy and the drug use regis-
tered in the hospital records (46). Seizure occurrence 
during pregnancy reported by the women was confir-
med by hospital records in 75% of the cases. Seizure 
freedom was confirmed in 89% of the cases. Age of 
epilepsy debut listed in the hospital records correlated 
strongly with the women’s self-reported data in MoBa 
(r=0.87, p<0.01, n = 24). 
 AEDs were detected in 95% of the plasma samples 
where the mother reported use of such medication 
during pregnancy. Maternal and umbilical cord mean 
plasma concentrations were in the middle of the refe-
rence interval for carbamazepine (Table 3). In contrast, 
mean levetiracetam, valproate, lamotrigine, oxcarba-
zepine and topiramate concentrations were in the lo-
wer part of the reference interval (Table 3). The mean 
daily dose was higher than recommended according to 
Norwegian guidelines (49) in the non-pregnant popula-
tion for lamotrigine (259 mg vs. a dose interval in mo-
notherapy of 100-200 mg) and topiramate (217 mg vs. 
100-200 mg), but lower for carbamazepine (574 mg 
vs. 800-1200 mg). The dose was in the normal range 
for valproate (754 mg vs. 10 mg/kg), oxcarbazepine 
(1125 mg vs. 600-2400 mg) and levetiracetam (1405 
mg vs. 1000-3000 mg). The correlations between dose 
and plasma concentrations in maternal and umbilical 
cord samples were 0.37 and 0.65 for carbamazepine 
(p=0.14 and < 0.01, respectively), 0.40 and 0.43 for 
lamotrigine (p=0.05 and 0.03, respectively), 0.55 and 
0.14 for levetiracetam (p=0.10 and 0.80, respectively), 
0.43 and 0.35 for valproate (p=0.29 and 0.49, respec-
tively) and 0.57 for the maternal topiramate samples 
(p=0.23). For oxcarbazepine and the umbilical cord 
topiramate samples the number of cases with both dose 
and concentration data available was too few to make 
meaningful correlations. 
 
Maternal risk factors for adverse offspring outcome  
Women with epilepsy treated with AEDs more often 
had low income and low education, were more often 
unemployed due to disability, single mothers, and 
smokers during pregnancy than women without epi-
lepsy. Use of alcohol and illicit drugs was similar 
between the groups (21). 
 Compared to women without epilepsy, women with 
epilepsy more often reported current or previous 
psychiatric disease (13.4% vs. 10.1%, p<0.01). Using 
screening tools, 19.4% of the AED treated and 14.0% 
of the untreated women with epilepsy screened posi-
tive for early pregnancy depression and/or anxiety, 
compared to 10.8% in the reference population 
(p<0.01 and p=0.05 respectively). For the AED treated 
women the risk was still significant after adjustment 
for age, education, income, unemployment, and single 
parenting (21). The point prevalence of depression and 
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Figure 1 legend: Adjusted odds ratio with 95 % confidence interval (log scale) for adverse 
development in children of parents with epilepsy compared to the reference group.  
SCQ: Social Communication Questionnaire (Previously Autism Screening Questionnaire).   
* P value < 0.05.  ** P value < 0.01.  Reprinted with kind permission from Epilepsia. Copyright 
John Wiley and Sons 2013©  
 
 
Figure 1.  Adjusted odds ratio with 95% confidence interval (log scale) for adverse development in children of parents with epilep-
sy compared to the reference group. SCQ: Social Communication Questionnaire (previously Autism Screening Questionnaire). 
* P value < 0.05. ** P value < 0.01. Reprinted with kind permission from Epilepsia. Copyright John Wiley and Sons 2013. 
 
 
anxiety was also increased late in pregnancy, in the 
postpartum period as well as 18 and 36 months after 
delivery for mothers with epilepsy using AEDs com-
pared to women without epilepsy. No specific AED 
typ  was found to protect against peripartum depres-
sion. High seizure frequency and previous anxiety 
and/or depression were the strongest risk factors (23). 
Women with epilepsy had a higher life-time prevalence 
of eating disorders, and more often had binge eating 
disorder during pregnancy than women without epi-
lepsy (21,22). 
 
Adverse offspring outcomes  
At 6 months of age, children of mothers reporting 
AED use during pregnancy (n=223) had a higher risk 
of impaired fine motor skills compared to the reference 
group (n=77,770) (OR 2.1, 95% CI 1.3–3.2 when ad-
justed for maternal age, education, folate supplement, 
smoking, breastfeeding and child malformation) (45). 
The risk was similar for monotherapy with lamotrigine, 
valproate, or carbamazepine. Children of mothers 
reporting use of multiple AEDs had the highest risk. In 
this group, 25% had impaired fine motor skills and 
23% had impaired social skills, in contrast to 4.8% and 
10%, respectively, in the reference group (p<0.05 after 
adjustment). Continuous breastfeeding during the first 
6 months after delivery was associated with a tendency 
towards improved outcome for all the developmental 
domains, regardless of maternal AED treatment (45). 
 At 18 months of age, children of mothers reporting 
AED use (n=184) had increased risk of autistic fea-
tures (adjusted OR 2.7, 95% CI 1.1–6.7), impaired fine 
motor skills (adjusted OR 1.8, 95% CI 1.0–3.4), gross 
motor skills (adjusted OR 2.0, 95% CI 1.1–3.7) and 
social skills (adjusted OR 2.2, 95% CI 1.3-3.6, Table 
4) compared to the reference group (n=60, 583) (46). 
At 36 months of age, these children (n=139) had a 
higher frequency of abnormal gross motor skills (ad-
justed OR 2.2, 95% CI 1.1–4.2), poor sentence skills 
(adjusted OR 2.1, 95% CI 1.2–3.6), and autistic traits 
(adjusted OR 3.4, 95% CI 1.6–7.0, Figure 1) than the 
reference group (n=43,571). The frequency of ADHD 
symptoms was similar between groups, but more 
aggressive behavior was seen in children of mothers 
reporting AED use (adjusted OR 1.8, 95% CI 1.0–3.4) 
(46). Compared to the reference group, risk estimates 
(confidence intervals) for all individual AED types 
were overlapping at 18 and 36 months, hence the 
individual AEDs were not different from each other. 
Children of fathers with epilepsy had a higher risk of  
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abnormal social skills (adjusted OR 2.3, 95% CI 1.3–
4.1) and autistic traits (adjusted OR 3.7, 95% CI 1.4– 
10.1) at 18 months of age compared to children of 
fathers without epilepsy, but this finding was not 
reproduced at 36 months of age (Figure 1). 
 Children of women with epilepsy who did not 
report use AEDs had normal development at all 





The MoBa epilepsy cohort  
The validity of self-reported epilepsy diagnosis and 
AED use was very good. Consequently, information 
on maternal disease and medication use during preg-
nancy registered in the MoBa database and the MBRN 
appears to be highly reliable. These results are of im-
portance for researchers investigating other disorders 
in the MoBa cohort, as the reliability might also apply 
for similar, chronic conditions, such as multiple 
sclerosis. As expected, AED plasma concentrations 
showed a low correlation to AED dose, which can be 
attributed to intraindividual variability in drug metabo-
lism and considerable changes in pharmacokinetics 
during pregnancy (11,12). Differences in drug-
adherence and recall bias may also play a role. The 
results indicate that plasma concentrations are a more 
reliable measure for AED exposure than dose. In 
previous studies, dose at the start of pregnancy has 
usually been used as a measure for degree of AED 
exposure (6,7,10). 
 The MoBa epilepsy cohort was representative for 
women with epilepsy in general. The self-reported 
epilepsy characteristics were similar to the cohort of 
Norwegian women included in the European and 
International Registry of Antiepileptic Drugs in Preg-
nancy (EURAP) database. The proportion of women 
with self-reported localization-related epilepsy in our 
cohort was 53% in the hospital records. The 
corresponding proportion in EURAP was 46% (50). 
However, the proportion of women with juvenile 
myoclonic epilepsy (22% in the self-reported group, 
15% in hospital records) was larger than the 5-10% 
normally seen in non-pregnant epilepsy populations. 
(51). This overrepresentation probably reflects that the 
MoBa cohort mainly consists of young (between 19 
and 41 years) and female participants, as there is a 
female preponderance in juvenile myoclonic epilepsy 
(51). Fewer women had seizures during pregnancy 
according to our studies (17% in the self-reported 
group, 15% in hospital records) than among the Nor-
wegian women in EURAP (37%) (50). However, the 
women in EURAP were recruited from neurological 
departments and a tertiary epilepsy center; hence the 
patients probably had more severe epilepsy compared 
to those in the population based MoBa cohort. How-
ever, the proportion of women having seizures during 
birth was similar between our data and the EURAP 
data (3.1% vs. 2.7%). 
The impact of AED exposure during pregnancy  
Our studies showed that exposure to AEDs in utero 
was associated with adverse effects on several key 
developmental domains at all measured time points. 
The exposed group did not reach motor milestones at 
the expected age, had poorer language skills, and more 
autistic behavior. The risk of impaired motor skills 
was detectable already at 6 months of age. The risk 
was generally highest for children exposed to multiple 
drugs. There was no difference between the various 
drugs when used in monotherapy. This is in contrast to 
previous studies which have found adverse develop-
mental outcomes mainly in relation to valproate expo-
sure in utero (3). Adverse socioeconomic factors and 
psychiatric disease were more frequent in women with 
epilepsy. However, the effect of AED exposure on 
offspring development persisted even after adjusting 
for these factors. 
 Children of mothers with epilepsy who did not use 
AEDs scored within the normal range for all develop-
mental domains, and children of fathers with epilepsy 
were mainly similar to the reference population. Thus, 
our results point to the in utero AED exposure as the 
main risk factor for adverse development in children of 
women with epilepsy. Maternal epilepsy severity was 
higher in the group using AEDs than in those not using 
AEDs (23). However, disease severity should be simi-
lar in fathers and mothers with epilepsy using AEDs, 
accounting for potential genetic or psychosocial effects 
on development in offspring of parents with active 
epilepsy. Frequent seizures during the pregnancy may 
affect later cognitive function (9). However, only 21 
women had generalized tonic clonic seizures during 
pregnancy or birth, and of these only 1 woman had 
more than 3 seizures. Prior research has indicated that 
less than 5 tonic clonic seizures during pregnancy do 
not seem to affect developmental outcome (9). Women 
using AEDs should be encouraged to breastfeed, as no 
harmful effects from maternal AED use during the 
breastfeeding period were detected. Breastfeeding has 
also been shown to improve cognitive outcome 
(52,53). 
 The main strengths of the MoBa epilepsy cohort is 
the prospective study design, the ability to adjust for 
numerous possible confounders, and the recruitment of 
a large and representative reference group that is nor-
mally not available in such studies (5,54). Including 
fathers with epilepsy as well as women with epilepsy 
not treated with AEDs as internal control groups is a 
unique feature of our study design. Due to the 
population-based enrollment, selection bias in the 
MoBa epilepsy cohort is probably much lower than in 
clinic-based studies, thereby providing results that may 
be more representative for general epilepsy popula-
tions. Even so, some degree of selection is probably 
present. It has e.g. been shown that the subjects in the 
MoBa study are more resourceful than the general po-
pulation; however this selection does not seem to affect 
exposure-outcome associations (55). Other weaknesses 
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in MoBa include a self-reported epilepsy diagnosis, 
developmental assessment based on maternal ratings, 
and a moderate response rate at 36 months. Even 
though the screening tools employed are validated, the 
short versions used in the questionnaires are not 
always so. The construct validity of the developmental 
MoBa screening tools has been criticized, e.g. with 
regard to what extent differences in scores actually 
represent meaningful clinical differences (56). This 
criticism does not necessarily apply to cut-offs that are 
set distant from the mean score, as performed in our 
studies. The construct validity is probably improved 
when the instruments are used to detect severe devia-
tions, such as in relation to considerable developmen-
tal delay. 
 This paper reports previously unpublished data on 
AED plasma levels measured in maternal and umbili-
cal cord plasma, and information on AED doses used 
during pregnancy. These data will be correlated to off-
spring developmental scores to search for dose/effect 
and concentration/effect relationships. The possibility 
to correlate the levels of AED exposure to future child 
outcomes from early age and throughout childhood in 
a population-based setting is unique. Moreover, the 
collection of clinical epilepsy data from a subcohort in 
MoBa has assured the quality of the dataset. Informa-
tion on seizures during pregnancy and epilepsy sub-
type is now at our disposal and we will assess the 
effect of these variables on various offspring outcomes. 
Finally, we have found higher BMI in women with 
epilepsy before and during pregnancy (22,46) and are 
currently studying the frequency of and risk factors 
associated with overweight, obesity and weight gain 
during pregnancy in the cohort. These factors are of 
considerable interest, as they are known to increase 
pregnancy complications in women without epilepsy 
(57,58). We will assess their impact on pregnancy out-
come in women with epilepsy in relation to AED use. 
CONCLUSIONS  
The validity of epilepsy-related information in the 
MoBa database was very good. The MoBa epilepsy 
cohort may be more representative for general epilepsy 
populations than studies based upon clinical materials.  
Use of the epilepsy cohort in MoBa has shown that 
AED exposure in utero is associated with impaired 
development and increased risk of autistic traits in the 
child. We will proceed with this cohort and analyze the 
impact of AED plasma concentrations and the contri-
bution of seizures during pregnancy, socioeconomic 
variables, psychiatric disease, vitamin deficiency and 
maternal overweight on the developing children born 
to mothers with epilepsy. The combination of such 
data is not available in other population-based studies 
of women with epilepsy in pregnancy. Hence, the 
unique design of the MoBa study will enable us to 
expand the knowledge within this field, entangling the 
various risk factors for adverse outcomes in children of 
women with epilepsy. 
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